AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2014
Oct 21, 2014
34057_dirs_2014-10-21_f1eb488d-f6e8-4bc8-96e7-71303a2eb03a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2014-10-21
Reporting Person: Burke Steven Keith (Sr. VP & Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.905 | 2016-08-01 | Common Stock (30411) | Direct | |
| Stock Option (Right to Buy) | $2.381 | 2017-09-10 | Common Stock (12287) | Direct | |
| Stock Option (Right to Buy) | $3.174 | 2019-06-19 | Common Stock (14898) | Direct | |
| Stock Option (Right to Buy) | $1.270 | 2021-10-26 | Common Stock (57934) | Direct | |
| Stock Option (Right to Buy) | $4.920 | 2024-06-23 | Common Stock (71218) | Direct | |
| Stock Option (Right to Buy) | $4.920 | 2024-06-23 | Common Stock (10696) | Direct |
Footnotes
F1: The shares underlying these options are fully vested.
F2: This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) in equal quarterly installments over four years.
F3: This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) 25% on the first anniversary of the grant date and the remaining shares in equal quarterly installments over the next three years.
F4: Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.